NCT06674759尚未招募4 期
Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis: a Randomized, Double-blind, Placebo-controlled Clinical Study
Guang'anmen Hospital of China Academy of Chinese Medical Sciences0 个研究点目标入组 72 人开始时间: 2025年1月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 72
- 主要终点
- Changes from Baseline to week 24 in Visual Analog Scale (VAS)score
研究概览
简要总结
The clinical trial has a research cycle of 24 weeks. The first 12 weeks are multicenter, randomized, double-blind, controlled trials. A total of 72 patients with knee osteoarthritis with liver-kidney deficiency syndrome and/or cold-dampness arthralgia syndrome are planned to be enrolled and randomly assigned to the control group (Tongren-Dahuoluo Bolus) and the treatment group (Tongren-Dahuoluo Bolus Placebo) in a 1:1 ratio. The purpose is to compare the safety and efficacy of Tongren-Dahuoluo Bolus and placebo in treating knee osteoarthritis. A long-term blind extension study will be conducted in the next 12 weeks. All subjects will take Tongren-Dahuoluo Bolus orally to evaluate the long-term safety, tolerability, and efficacy of Tongren-Dahuoluo Pills in treating patients with knee osteoarthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, aged 40 to 75 years old;
- •Meet the diagnostic criteria for primary knee osteoarthritis (KOA) (the diagnostic criteria refer to the 1995 American College of Rheumatology classification criteria for knee osteoarthritis);
- •Meet the diagnostic criteria for liver and kidney deficiency and (or) cold and dampness obstruction in the group standard of the Chinese Association of Traditional Chinese Medicine "Guidelines for Combination of Osteoarthritis Symptoms";
- •X-ray examination of the joints is graded as I to III (knee joint Kellgren/Lawrence e scoring standard);
- •Knee pain score ≥40mm in the past week (assessed by VAS standard);
排除标准
- •Patients with other rheumatic diseases such as Sjögren's syndrome, gout, rheumatoid arthritis, or a history of human immunodeficiency virus (HIV);
- •Patients with severe lesions of important organs such as the heart, liver, and kidney, abnormal liver function (alanine or aspartate aminotransferase or glutamine transpeptidase>1.5 times the upper limit of normal value); or abnormal renal function (serum creatinine level> upper limit of normal value); white blood cell (white blood cell, WBC) or platelet (platelet, PLT) below the lower limit of normal value; or diabetic patients with poor blood sugar control in the recent period (glycosylated hemoglobin>8.0%);
- •Patients with suppurative, nonspecific, and other infectious knee arthritis;
- •Patients with traumatic, villonodular pigmentation and other lesions with knee synovium as the main lesions;
- •Patients with advanced joint deformity or disability; A randomized controlled study on Tongren Dahuoluowan in the treatment of knee osteoarthritis Version number: 2023009P8A01 Version date: December 23, 2022
- •Allergic constitution and allergic to the test drug;
- •Pregnant, pregnant, or lactating women;
- •Those who are taking antidepressants, anticonvulsants, opioids, sedatives and glucocorticoids;
- •Patients who have received intra-articular treatment with sodium hyaluronate within 4 weeks before screening; those who have taken drugs containing chondroitin sulfate/glucosamine/diacerein within 3 months before screening; those who have used biological agents within 3 months before screening;
- •Patients with organ failure symptoms;
- •Those who have participated in any other drug trials within 1 month before selection;
- •Those who the researcher believes are not eligible to join this clinical trial
研究组 & 干预措施
Treatment of Tongren Dahuoluo Pills
Experimental
干预措施: Tongren-Dahuoluo Bolus (Drug)
Treatment of Tongren-Dahuoluo Bolus Placebo
Placebo Comparator
干预措施: Tongren-Dahuoluo Bolus Placebo (Drug)
结局指标
主要结局
Changes from Baseline to week 24 in Visual Analog Scale (VAS)score
时间窗: 0 week, 4 weeks,12 weeks, 24 weeks
VAS scores ranges from 0 to 100, with higher scores indicating heavier pain
次要结局
- Changes in the 30s-CST frequency (30-second chair sit-stand test) of the experimental group relative to the baseline and control group at the 4th, 12th, and 24th weeks;(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in knee osteoarthritis index (WOMAC score) at week 4, week 12, and week 24 relative to baseline and control group(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in TCM syndrome score evaluation at week 4, week 12, and week 24 relative to baseline and control group;(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in KOOS scores of knee injury and osteoarthritis outcomes at weeks 4, 12, and 24 relative to baseline and the control group(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in SF-12 at week 4, week 12, and week 24 relative to baseline and control group(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in serum inflammatory indicators (CRP) relative to baseline and control group at week 4, week 12, and week 24(0 week, 4 weeks,12 weeks, 24 weeks)
- Changes in serum inflammatory indicators (ESR) relative to baseline and control group at week 4, week 12, and week 24(0 weeks, 4 weeks,12 weeks, 24 weeks)
- MRI examination of the knee joint (target joint) at the time of enrollment and at week 24 to examine the changes in bone marrow edema, joint effusion, synovitis, cartilage volume and composition relative to the baseline and control group(0 week, 4 weeks,12 weeks, 24 weeks)
研究者
Quan Jiang
Director，Devision of Rheumatology
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
相似试验
已完成
3 期
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT00624286Novartis416
Unknown
2 期
Efficacy and Safety of Kochujang Pills on Improvement of Blood LipidsHyperlipidemiaNCT01735149Chonbuk National University Hospital60
已完成
4 期
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.Pulmonary Disease, Chronic ObstructiveNCT00388882Boehringer Ingelheim327
已完成
3 期
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT00794157Novartis Pharmaceuticals347
已完成
2 期
A New Oral Treatment For Type II Diabetes MellitusDiabetes Mellitus, Type 2NCT00111800GlaxoSmithKline375